KLOW Dosage Chart.

Twenty units, and the fact that this question has a surprising answer is the single most important thing on this page. BPC-157 is 10 mg of an 80 mg vial, so it is only 12.5% of the blend by mass. To deliver 500 mcg of BPC-157 you need 4 mg of blend, which at 20 mg/mL is 20 units. If you instead draw "500 mcg" off the vial because that is the number you read in a standalone BPC-157 protocol, you get 2.5 units and 62.5 mcg of BPC-157, one eighth of what you intended. Work every dose from the component you care about, multiply up by its share of the blend, then convert to units.

The common spec is 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500 and 10 mg KPV. By mass that is 62.5% GHK-Cu and 12.5% each of the other three, which means a KLOW dose is mostly a GHK-Cu dose with three smaller peptides riding along. That ratio is fixed in the vial and you cannot change it; you can only scale the whole thing up or down. Check your own label or COA before copying any unit count, because KLOW is a vendor name rather than a standardised formula and other splits are sold.

KLOW is GLOW plus KPV, the K on the front. GLOW is GHK-Cu, BPC-157 and TB-500; KLOW adds 10 mg of KPV, the lysine-proline-valine tripeptide that forms the C-terminal fragment of α-MSH. The reason to pay for the fourth component is that KPV targets inflammation through a different route from the other three: it suppresses NF-κB and MAP kinase signalling, which is why it is associated with gut and skin inflammatory conditions rather than tendon repair. Whether that translates to an injected human dose is unstudied. If inflammation is not what you are treating, GLOW does the same job for less.

GHK-Cu, which is 62.5% of the blend by mass. Copper complexes irritate subcutaneous tissue in a way plain peptides do not. Four things genuinely help: reconstitute to a larger volume (5 mL instead of 4 mL cuts the concentration by a fifth for the same mg; just recalculate your units), let the vial come to room temperature instead of injecting it cold from the fridge, push the plunger slowly over several seconds, and use abdominal fat rather than thin-skinned areas like the upper arm. If it still welts up every time, that is an amber sign to drop a tier.

GHK-Cu is about 15.8% elemental copper by mass (molecular weight ~402, copper 63.5). At the standard 20 units you are getting 2.5 mg of GHK-Cu, so roughly 395 mcg of copper per shot, under the 900 mcg daily RDA and far under the 10 mg/day tolerable upper limit. Here is the catch: both of those figures are for dietary copper, where your gut actively regulates how much crosses over. Injected copper skips that regulation entirely, so the oral numbers do not tell you what is safe here, and no one has established a parenteral ceiling. That is the real argument for cycling and for not creeping past 25 units.

If you have a specific target, yes. Separate vials let you run BPC-157 at 250–500 mcg daily, KPV at 250–500 mcg daily, GHK-Cu at 1–2 mg daily and TB-500 at 2–5 mg twice weekly, each at its own conventional dose and, importantly, on its own schedule, which for TB-500 is genuinely different from the other three. KLOW cannot do that: one ratio, one syringe, one frequency. Its real advantage is one injection instead of four and one vial instead of four, which is a fair trade if adherence is your problem. If you are rehabbing a specific injury or treating a specific gut condition, it is not.

Common practice is 4–6 weeks on and 2–4 weeks off, stretching to 6–8 weeks for recovery-focused runs. No human study has followed any of these four compounds past 12 weeks by any route, so continuous use is unstudied territory. The reason usually given for cycling (preventing receptor desensitisation) has no data behind it and does not really fit how these peptides work. The defensible reason to take off-weeks is the copper: repeated parenteral GHK-Cu accumulates exposure your gut never gets to moderate, and off-weeks cap it. If you are running back-to-back cycles for months, get serum copper and ceruloplasmin checked.

No. None of the four components is approved for any indication in any country, and no regulator has ever evaluated them as a blend. In September 2023 the FDA placed BPC-157 and thymosin beta-4 fragment into Category 2 of its interim 503A bulk drug substances policy: substances judged to present significant safety risks, which compounding pharmacies could not use. In 2026 that position moved: the outside nominations were withdrawn and FDA removed the substances from Category 2, which did not move them to Category 1 and did not put them on the final 503A Bulks List, and the agency's Pharmacy Compounding Advisory Committee subsequently voted to recommend BPC-157 and TB-500 for that list. A recommendation is not a rule change; formal rulemaking still has to happen. Nothing sold today as "research use only" is covered by any of it.

Under WADA rules, yes. BPC-157 has been prohibited under S0 (non-approved substances) since January 2022, and TB-500 and thymosin β4 derivatives under S2.3 (growth factors and growth factor modulators) since 2018. Both are banned in and out of competition and are non-specified substances, meaning no reduced sanction for an accidental positive, and a validated plasma and urine assay for the TB-500 fragment has existed since 2012. Enforcement can also be non-analytical: possession, an order confirmation or an admission is enough to bring a case with no positive sample at all. Standard workplace and clinical panels do not screen for any of this; they test for something else entirely.